Murphy, Middleton, Hinkle & Parker, Inc. Bristol Myers Squibb CO Transaction History
Murphy, Middleton, Hinkle & Parker, Inc.
- $172 Million
- Q2 2024
A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 8,478 shares of BMY stock, worth $459,338. This represents 0.2% of its overall portfolio holdings.
Number of Shares
8,478
Previous 8,478
-0.0%
Holding current value
$459,338
Previous $459,000
23.31%
% of portfolio
0.2%
Previous 0.27%
Shares
11 transactions
Others Institutions Holding BMY
# of Institutions
2,404Shares Held
1.5BCall Options Held
29.7MPut Options Held
32.2M-
Vanguard Group Inc Valley Forge, PA187MShares$10.1 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.6 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.95 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$4.04 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$3.2 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $115B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...